Condition: Myasthenia Gravis, Generalized · Sponsor: Dianthus Therapeutics
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
This description comes directly from the study's public registry record.
Dianthus Clinical Contact Center · 929-999-4055 · clinicaltrials@dianthustx.com
Always discuss trial participation with your own doctor first.
| Cinical Study Site | Fayetteville, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07647510